Prof. François-Clément Bidard and Dr Barbara Pistilli share expert insights on the latest TROPION-Breast01 update, presenting the final OS results from the ESMO Virtual Plenary 2025.
This study evaluates datopotamab deruxtecan (Dato-DXd) versus chemotherapy in previously treated, inoperable or metastatic HR+/HER2– breast cancer.
In this video, the experts explore:
- Mechanism of action of Dato-DXd
- TROPION-Breast01 PFS results and safety outcomes
- Final overall survival results and their clinical implications
- The future outlook for Dato-DXd
Clinical takeaways
- TROPION-Breast01 final OS results did not reach statistical significance; however, subsequent ADC treatment may have influenced survival outcomes
- The dual primary endpoint of PFS demonstrates a statistically significant and clinically meaningful improvement with Dato-DXd compared with chemotherapy
- Secondary efficacy and PRO endpoints continued to show a benefit for Dato-DXd in this final analysis
Download the Virtual Plenary slides from ESMO's OncologyPro website: www.oncologypro.esmo.org
 
                                        
                                        
                               
                           
 
       
                         Downloadable
                  Downloadable  MIN
                MIN
             Oct 2025
               Oct 2025             
                         
                            
                            
                            
                            
                                           
                   
                         
                         
                         
                         
                         
                            
                            
                            
                   
                         
                         
                            
                            
                            
                   
                         
                            
                        